Radiotherapy Delays Malignant Transformation and Prolongs Survival in Patients with IDH-mutant Gliomas

Overview

Journal Cancer Biol Med

Specialty Oncology

Date 2022 Nov 9

PMID 36350001

Authors

Yanwei Liu

Huiyuan Chen

Guanzhang Li

Jing Zhang

Kun Yao

Chenxing Wu

Shouwei Li

Xiaoguang Qiu

Affiliations

Soon will be listed here.

Abstract

Objective: IDH-mutant lower-grade gliomas (LGGs, grade 2 or 3) eventually transform into secondary grade 4 astrocytomas (sA). Here, we sought to describe the transformation time, risk factors, and outcomes in malignant transformation of IDH-mutant LGGs.

Methods: We screened data for 108 patients with sA in the Chinese Glioma Genome Atlas who had initial IDH-mutant LGGs and underwent reoperation during 2005-2021. We evaluated the transformation time from IDH-mutant LGGs to sA, and associated risk factors and outcomes. Malignant transformation was defined as pathological confirmation of grade 4 astrocytoma.

Results: The median age of the 108 patients with IDH-mutant LGGs was 35 years (range, 19-54); the median age at transformation was 40 years (range, 25-62); and the median follow-up time for all patients was 146 months (range, 121-171). The average transformation time was 58.8 months for all patients with LGGs (range, 5.9-208.1); 63.5 and 51.9 months for grade 2 and 3 gliomas, respectively; and 58.4 and 78.1 months for IDH-mutant/1p/19q-non-codeleted astrocytomas and IDH-mutant/1p/19q-codeleted oligodendrogliomas, respectively. Univariate and multivariate analysis indicated that radiotherapy [hazard ratio (HR), 0.29; 95% confidence interval (CI), 0.137-0.595; = 0.001] and non-A blood type (HR, 0.37; 95% CI, 0.203-0.680; = 0.001) were protective factors against delayed malignant transformation. Radiotherapy was associated with improved survival after transformation (HR, 0.44; 95% CI, 0.241-0.803; = 0.008), overall survival (HR, 0.50; 95% CI, 0.265-0.972; = 0.041), and progression-free survival (HR, 0.25; 95% CI, 0.133-0.479; < 0.0001) in patients with IDH-mutant gliomas.

Conclusions: Radiotherapy is associated with delayed malignant transformation and improved survival in patients with IDH-mutant gliomas.

Citing Articles

Malignant Transformation of Meningiomas.

Yu J, Deng J, Ren L, Hua L, Gong Y J Cancer. 2025; 16(5):1684-1693.

PMID: 39991581 PMC: 11843249. DOI: 10.7150/jca.105024.

Significance of radiation therapy in frontal glioblastoma patients and exploration of optimal treatment modality: a real-world multiple-center study based on propensity score matching.

Li N, Hao S, Cao X, Lin Y, Li Y, Dai T Quant Imaging Med Surg. 2024; 14(10):7576-7586.

PMID: 39429582 PMC: 11485375. DOI: 10.21037/qims-23-1871.

A patient-derived cell model for malignant transformation in IDH-mutant glioma.

Kim O, Sergi Z, Yu G, Yamamoto K, Quezado M, Abdullaev Z Acta Neuropathol Commun. 2024; 12(1):148.

PMID: 39256867 PMC: 11385154. DOI: 10.1186/s40478-024-01860-6.

Deubiquitinase USP14 is upregulated in Crohn's disease and inhibits the NOD2 pathway mediated inflammatory response .

Li M, Zhao Y, Zhang J, Jiang W, Peng S, Hu J Eur J Histochem. 2024; 68(3).

PMID: 39252535 PMC: 11445697. DOI: 10.4081/ejh.2024.4101.

Glioblastoma with a primitive neuronal component: A case report.

Ma Q, Liu L, Sun N, Gao L, Chen Y, Liu L Oncol Lett. 2023; 26(2):341.

PMID: 37427343 PMC: 10326655. DOI: 10.3892/ol.2023.13927.

References

Ellingson B, Chung C, Pope W, Boxerman J, Kaufmann T . Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol. 2017; 134(3):495-504. PMC: 7893814. DOI: 10.1007/s11060-017-2375-2. View

Qazi M, Vora P, Venugopal C, Sidhu S, Moffat J, Swanton C . Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Ann Oncol. 2017; 28(7):1448-1456. DOI: 10.1093/annonc/mdx169. View

Jiang T, Nam D, Ram Z, Poon W, Wang J, Boldbaatar D . Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2020; 499:60-72. DOI: 10.1016/j.canlet.2020.10.050. View

Wang Z, Liu L, Ji J, Zhang J, Yan M, Zhang J . ABO blood group system and gastric cancer: a case-control study and meta-analysis. Int J Mol Sci. 2012; 13(10):13308-21. PMC: 3497328. DOI: 10.3390/ijms131013308. View

Baumert B, Hegi M, van den Bent M, von Deimling A, Gorlia T, Hoang-Xuan K . Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016; 17(11):1521-1532. PMC: 5124485. DOI: 10.1016/S1470-2045(16)30313-8. View

Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I . A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature. 2021; 592(7854):463-468. PMC: 8046668. DOI: 10.1038/s41586-021-03363-z. View

Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C . An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013; 340(6132):626-30. PMC: 3985613. DOI: 10.1126/science.1236062. View

Bell E, Zhang P, Shaw E, Buckner J, Barger G, Bullard D . Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. J Clin Oncol. 2020; 38(29):3407-3417. PMC: 7527157. DOI: 10.1200/JCO.19.02983. View

Hu L, Baxter L, Smith K, Feuerstein B, Karis J, Eschbacher J . Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced.... AJNR Am J Neuroradiol. 2008; 30(3):552-8. PMC: 7051449. DOI: 10.3174/ajnr.A1377. View

10.

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

11.

Wong Q, Li K, Wang W, Malta T, Noushmehr H, Grabovska Y . Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas. Mod Pathol. 2021; 34(7):1245-1260. DOI: 10.1038/s41379-021-00778-x. View

12.

Shaw E, Berkey B, Coons S, Bullard D, Brachman D, Buckner J . Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg. 2008; 109(5):835-41. PMC: 3833272. DOI: 10.3171/JNS/2008/109/11/0835. View

13.

Venteicher A, Tirosh I, Hebert C, Yizhak K, Neftel C, Filbin M . Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science. 2017; 355(6332). PMC: 5519096. DOI: 10.1126/science.aai8478. View

14.

Liu Y, Li Y, Wang P, Chen L, Feng J, Qiu X . High-dose radiotherapy in newly diagnosed low-grade gliomas with nonmethylated O(6)-methylguanine-DNA methyltransferase. Radiat Oncol. 2021; 16(1):157. PMC: 8375106. DOI: 10.1186/s13014-021-01878-3. View

15.

van den Bent M, Afra D, De Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K . Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005; 366(9490):985-90. DOI: 10.1016/S0140-6736(05)67070-5. View

16.

Strauss S, Meng A, Ebani E, Chiang G . Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis. Radiol Clin North Am. 2019; 57(6):1199-1216. DOI: 10.1016/j.rcl.2019.07.003. View

17.

Wang Y, Li S, Chen L, You G, Bao Z, Yan W . Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro Oncol. 2012; 14(4):518-25. PMC: 3309852. DOI: 10.1093/neuonc/nor232. View

18.

Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J . Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Cell. 2018; 175(6):1665-1678.e18. DOI: 10.1016/j.cell.2018.09.038. View

19.

Murphy E, Leyrer C, Parsons M, Suh J, Chao S, Yu J . Risk Factors for Malignant Transformation of Low-Grade Glioma. Int J Radiat Oncol Biol Phys. 2018; 100(4):965-971. DOI: 10.1016/j.ijrobp.2017.12.258. View

20.

Dang L, Yen K, Attar E . IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol. 2016; 27(4):599-608. DOI: 10.1093/annonc/mdw013. View